Table 1.
Demographic characteristics and laboratory findings of ANCA-positive patients in 2019 and 2021
| 2019 (n = 15) | 2021 (n = 35) | p | |
|---|---|---|---|
| Age, years, mean (SD) | 65.8 (14.6) | 63.1 (16.4) | 0.969 |
| Sex, females, n (%) | 6 (40.0%) | 19 (54.3%) | 0.537 |
| ANCA or anti-GBM Ab, n (%) | |||
| Anti-MPO Ab | 11 (73.3%) | 16 (45.7%) | 0.137 |
| Anti-PR3 Ab | 2 (13.3%) | 15 (42.9%) | 0.090 |
| Anti-GBM Ab | 1 (6.7%) | 2 (5.7%) | 0.603 |
| Anti-MPO + anti-PR3 Ab | 1 (6.7%) | 1 (2.9%) | 0.875 |
| Anti-MPO + anti-GBM Ab | — | 1 (2.9%) | — |
SD, standard deviation; ANCA, antineutrophil cytoplasmic antibodies; MPO, myeloperoxidase; PR3, proteinase 3; GBM, glomerular basal membrane; Ab, antibody.